Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InventivaXTER:6IV 35 3-1 Month Momentum % is N/A% as of Sep. 01, 2026. GuruFocus rates XTER:6IV with a GF Score™ of 35/100 and a GF Value™ of €0.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,379 Biotechnology companies, Inventiva ranks worse than 52.57% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-01), Inventiva's 3-1 Month Momentum % is N/A%.
The industry rank for Inventiva's 3-1 Month Momentum % or its related term are showing as below:
XTER:6IV's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -10.27 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventiva (XTER:6IV) has a 3-1 Month Momentum % of N/A% as of Sep. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inventiva and its competitors. According to the industry distribution chart, Inventiva ranks #725 out of 1379 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Inventiva's 3-1 Month Momentum % too high?
Inventiva's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Inventiva ranks #725 out of 1379 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inventiva has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inventiva ranks #725 out of 1379 companies for 3-1 Month Momentum %. This places Inventiva in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inventiva and its competitors. Inventiva's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (XTER:6IV) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.25, compared to a current price of €4.36 — trading 1644% above its estimated fair value. The current 3-1 Month Momentum % is N/A%. Inventiva's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Inventiva (XTER:6IV), the current 3-1 Month Momentum % is N/A% as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inventiva (XTER:6IV) Overvalued in 2026?
Based on GuruFocus' analysis, Inventiva stock appears to be overvalued.
The current stock price of €4.36 is trading 1644% above its estimated GF Value™ of €0.25.
GuruFocus considers Inventiva to be Significantly Overvalued.
Key valuation signals for XTER:6IV:
3-1 Month Momentum %: N/A%
GF Value™: €0.25 vs. price of €4.36 (1644% above fair value)
No single metric tells the full story. See the XTER:6IV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
35GF Score
Get the complete analysis for XTER:6IV
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:6IV has been successfully added to your 
